Hib meningococcal vaccine groups A and C conjugate - Jiangsu Provincial Center for Disease Control and Prevention/Wuxi Royal Biological

Drug Profile

Hib meningococcal vaccine groups A and C conjugate - Jiangsu Provincial Center for Disease Control and Prevention/Wuxi Royal Biological

Alternative Names: A+C+hib Conjugate Vaccine; Group A, C polysaccharide meningococcal and type b haemophilus Influenzal Conjugate vaccine; Hib-MenAC; MenAC-Hib; Meninogococcal vaccine groups A and C Hib conjugate

Latest Information Update: 24 Nov 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Jiangsu Provincial Center for Disease Control and Prevention
  • Developer Jiangsu Provincial Center for Disease Control and Prevention; Wuxi Royal Biological
  • Class Haemophilus vaccines; Meningococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Haemophilus infections; Meningococcal group A infections; Meningococcal group C infections

Most Recent Events

No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top